Collegium Pharmaceutical, Inc (COLL): Cost of Revenue
$317.31M
Year ended 2025-12-31
$323.12M
Trailing 12 months to 2026-06-30
+7.6%
3-year compound annual growth
+19.5%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $317.31M | +24.9% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $254.10M | +5.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $240.60M | -5.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $254.44M | +101.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $126.25M | -3.0% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $130.18M | -32.8% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $193.66M | +16.9% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $165.68M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $2.60M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $213.0K | n/a | 2019-02-27, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $317.31M | +24.9% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $12.98M | +19.3% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $326.20M | -52.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $149.75M | -12.1% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $363.83M | +1.6% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $74.56M | -4.3% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $198.34M | +26.5% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $77.67M | +27.5% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $15.91M | +41.9% |
Compare COLL, CORT, EBS, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗